Tag: Asia Pacific

Healthcare Industry Asia-Pacific Cosmeceuticals Industry Research Report

Posted on by admin

The desire of each individual to retain a youthful appearance has stipulated the demand for cosmeceuticals which can neither be categorized as cosmetics or pharmaceuticals, thus strengthening the market for cosmeceuticals in Asia Pacific region. The utility of cosmeceuticals has considerably risen in recent years. This radically inclined the techniques of clinician in improving the treatment of skin, hair and other conditions. The value growth of cosmeceutical products over the years has been impelled by changing consumer perception. Asian men are becoming considerable consumers of dermaceutical products, providing opportunities for various companies that feature men’s lines such as skin care, shaving and other products.

The distribution of cosmeceutical products through various online channels has grown at a rapid pace in the past few years. Departmental stores and hypermarkets in the past have played a vital role in the development of dermaceutical product market.

The cosmeceuticals market in Asia-Pacific region will grow rapidly from 2013-2017, as people in the countries of India, Indonesia, Thailand, Vietnam and Malaysia have become health conscious and desire to look fair and young. The industry forecast shows strong growth in skin care and hair care segments and also significant growth is expected in other niche areas such as lip protection and teeth whitening in Asia-Pacific region.

Clinical research combined with innovative expansion of new ingredients in the medicated hair care and skin care products will maintain the cosmeceutical segment of the cosmetics market attractive and lucrative.

The report titled -Asia-Pacific Cosmeceuticals Industry Forecast to 2017 – Medicated Cosmetics Present Bright Prospects- offers a detailed study of the Asian cosmeceuticals market and help to analyze further prospects in the various parts of the region. It facilitate the cosmeceutical producers, marketers and emerging companies to understand market trends by geography and by product lines to form strategies, make new alliances, expand product line and audience to target. Statistical information provides deep understanding of industry past performance, present and future prospects on account of changing economic conditions and shifting consumer buying habits.

Read More:

Contact Person: Ankur Gupta

E-mail:

Head And Neck Cancer – Pipeline Assessment And Market Forecast To 2017

Posted on by admin

GlobalData expects the global head and neck cancer therapeutics market to grow at a rate of 7.6% annually for the next seven years to reach $1,854m by 2017. It was valued at $1,035m in 2009. This significant growth is primarily attributed to the high incidence, prevalence and diagnosis rate of the disease and the high prescription rates of the currently approved products. In addition, the successful launch of certain biologics, gene therapies and vaccines such as Reolysin, OncoVEX and nimotuzumab, currently in Phase III, may significantly stimulate market growth in the near future. However, the low treatment seeking rate and the widespread use of off-label drugs will act as barriers for market growth.

GlobalDatas analysis has found that the current competition in the head and neck cancer market is weak. The competitive landscape is sparsely populated with only two FDA (Food and Drug Administration)-approved products. The market is characterized by high off-label usage of drugs such as cisplatin, paclitaxel carboplatin and combination therpaies. The currently marketed products are not highly efficacious and so are not able to meet market demands such as improved five-year survival rates, reductions in tumor sizes and the control of tumor recurrence. However, the development of technologically advanced products such as vaccines, gene therapy and biologics in different stages of the pipeline promises to provide better options for treatment.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Head-and-Neck-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

GlobalData has found that there are 405 products in different stages of development. Reolysin, Oncovex and nimotuzumab, currently in Phase III, are some of the most promising products in the pipeline. Biologics, gene therapy, vaccines and other molecular targeted therapies make the pipeline robust enough to meet the unmet needs of the head and neck cancer market. The pipeline holds novel products which are technologically advanced and have high efficacy and safety profiles. The efficacy and safety of biologics such as nimotuzumab (approved in 23 countries and undergoing Phase III studies in the US) are high in terms of complete response, progression-free survival, improved tolerability and high safety profiles. Additionally, some of the oncolytic vaccines currently in Phase III, such as Oncovex, offer systematic benefits by inducing a potent anti-tumor immune response, as well as the prevention of new lesions and a lowering of the relapse rate.

GlobalData, the industry analysis specialists new report, Head and Neck Cancer – Pipeline Assessment and Market Forecast to 2017 is an essential source of information and analysis on the global head and neck cancer market. The report identifies the key trends shaping and driving the global head and neck cancer market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global head and neck cancer sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalDatas team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Head-and-Neck-Cancer-Drug-Pipeline-Analysis-and-Market-Forecasts-to-2016&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.globaldata.com

For more details contact:
[emailprotected]
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

Thyroid Cancer Therapeutics – Pipeline Assessment And Market Forecast To 2017

Posted on by admin

GlobalData estimated that the thyroid cancer market was worth $55m in 2010. The major reason for the limited market revenues was the lack of approved drugs for the treatment of thyroid cancer. Thyroid cancer is mainly treated by surgery and radiotherapy. Chemotherapy has fewer roles to play in the treatment. Mainly doxorubicin is used as an off-label drug for treating the patients with anaplastic thyroid cancer; also some other off-label drugs such as cisplatin and carboplatin are used, but they have lower response rates. The high growth forecast for the thyroid cancer therapeutics market is primarily attributed to a strong pipeline. The upcoming four pipeline molecules (Pre-registration (1) and Phase III (3)) in the next seven years will take a steep rise in the market. Overall, between 2010 and 2017, the thyroid cancer market is expected to grow at a CAGR (Compound Annual Growth Rate) of 27.34% to reach $298m by 2017.

GlobalData found that the pipeline of the thyroid cancer market is strong, as there are 27 molecules in different stages of development. There are four promising molecules in Pre-registration (1) and Phase III (3). These drugs are expected to get approved in the next seven years. Zactima, Zybrestat and XL184 have been granted orphan drug status by the FDA.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Thyroid-Cancer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report

These new molecules with novel mechanisms of action will meet the current unmet needs and will give physicians a better choice for the treatment of thyroid cancer. Once these molecules get approved it will intensify competition in the market. In summary, the global thyroid cancer therapeutics market is heading towards a strong competitive landscape.

GlobalData found that the current competition in the thyroid cancer market is weak, as the market is devoid of any approved drug treatment. Surgery is the most effective mode of treatment. Some chemotherapy drugs are used off-label, such as doxorubicin which is aimed at managing conditions that contribute to thyroid cancer. Hence, there is an open space for a company to enter into this market and take substantial market share.

GlobalData, the industry analysis specialist, has released its new report, Thyroid cancer Therapeutics – Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global thyroid cancer therapeutics market. The report identifies the key trends shaping and driving the global thyroid cancer therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to sithyroid cancerificantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global thyroid cancer therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Thyroid-Cancer-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2017&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthcare

Visit our report store: http://www.globaldata.com

For more details contact:
[emailprotected]
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782

© 2025 Force Health Care